Annovis Bio(ANVS.US)

Last Updated 19:00:00 ET
longbridge loading

Annovis Bio Regains NYSE Compliance Ahead Of 18-Month Cure Period

nasdaq·
US
ANVS
-2.73%
nasdaq·
US
ANVS
-2.73%

Annovis Bio Launches ~$15 Million Stock-and-Warrant Offering Underwritten by Canaccord Genuity

TradingView·
US
ANVS
-2.73%
TradingView·
US
ANVS
-2.73%

Annovis Bio Announces Offering Of Shares And Warrants To Advance Buntanetap In AD; Stock Down

nasdaq·
US
ANVS
-2.73%
nasdaq·
US
ANVS
-2.73%

12 Health Care Stocks Moving In Tuesday's After-Market Session

benzinga_article·
US
CLDX
+4.37%
US
GLUC
-13.42%
US
CODX
-8.72%
benzinga_article·
US
CLDX
+4.37%
US
GLUC
-13.42%
US
CODX
-8.72%

Annovis Bio | 8-K: FY2026 Q1 Revenue: USD 0

Earnings Watch·
US
ANVS
-2.73%
Earnings Watch·
US
ANVS
-2.73%

Annovis Bio Prices Registered Direct Offering to Fund Trials

Tip Ranks·
US
ANVS
-2.73%
US
FBT
-0.71%
US
IBBQ
+0.24%
Tip Ranks·
US
ANVS
-2.73%
US
FBT
-0.71%
US
IBBQ
+0.24%

Annovis Bio shares are trading lower after the company announced pricing of its $10 million offering of common stock and warrants.

benzinga_article·
US
ANVS
-2.73%
US
IHI
0.00%
US
PBE
-0.85%
benzinga_article·
US
ANVS
-2.73%
US
IHI
0.00%
US
PBE
-0.85%
© 2026 Longbridge｜Disclaimer